2015 ASCO Journal Club: Genitourinary Cancers Fourth Quarter

Each quarter, ASCO's experts review the leading journals, including the Journal of Clinical Oncology, to compile the most relevant, practice-changing science in genitourinary cancers. Reviews are presented in a didactic slide format, with audio commentary and links to references and resources and will focus on the following areas: translational science, clinical trials, reviews, guidelines, and editorials. Articles covered in this quarter's review include:

  • Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20;373(8):737-46. 
  • Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1814-23
  • Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1803-13.

Learning Objectives
Sweeney paper

  • Explain that prostate cancer is heterogeneous and is composed of both hormone sensitive and hormone resistant cells
  • Determine the difference between low volume and high volume metastatic prostate cancer
  • Examine the results of this study to different categories of high and low risk metastatic patients
  • Apply the knowledge learned to enhance the care delivered to patients with metastatic prostate cancer

Choueiri paper

  • Understand that resistance to targeted therapy is a major challenge to improving clinical outcomes in patients with RCC
  • Describe the mechanism of action of Cabozantinib
  • Define the toxicities associated with Cabozantinib
  • Realize that Cabozantinib represents a potential new option for 2nd or later line therapy for RCC as compared to everolimus which has been the benchmark for comparison

Motzer paper

  • Explain that immunotherapy can provide significant tumor shrinkage in clear cell RCC, and  even stable disease can translate into long-term survival benefits
  • Understand that progression free survival and PDL-1 expression don’t  reflect overall survival in patients treated with immunotherapy
  • Examine the side effects associated with checkpoint inhibition
  • Recognize that for the first time a advantage in overall survival has been obtained in the 2nd line setting in patients with mRCC

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred. 

Important Notes

  • This course expires on December 16, 2018. Participants must complete all necessary course components by this date to receive credit.